SEARCH

SEARCH BY CITATION

References

  • Apperley, J.F. (2007) Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. The Lancet Oncology, 8, 10181029.
  • Ben-Neriah, Y., Daley, G.Q., Mes-Masson, A.M., Witte, O.N. & Baltimore, D. (1986) The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science, 233, 212214.
  • Chase, A. & Cross, N.C. (2006) Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases. Clinical Science (London, England: 1979), 111, 233249.
  • Cullen, P.J. (2008) Endosomal sorting and signalling: an emerging role for sorting nexins. Nature Reviews. Molecular Cell Biology, 9, 574582.
  • Deenik, W., Beverloo, H.B., van der Poel-van de Luytgaarde, S.C., Wattel, M.M., van Esser, J.W., Valk, P.J. & Cornelissen, J.J. (2009) Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia. Leukemia, 23, 627629.
  • Deininger, M., O’Brien, S.G., Guilhot, F., Goldman, J.M., Hochhaus, A., Hughes, T.P., Radich, J.P., Hatfield, A.K., Mone, M., Filian, J., Reynolds, J., Gathmann, I., Larson, R.A. & Druker, B.J. (2009) International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) Treated with Imatinib. Blood (ASH annual meeting abstracts), 114, [1126].
  • Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S. & Sawyers, C.L. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine, 344, 10311037.
  • Escherich, G., Horstmann, M.A., Zimmermann, M. & Janka-Schaub, G.E. (2010) Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97. Leukemia, 24, 298308.
  • Hidalgo-Curtis, C., Chase, A., Drachenberg, M., Roberts, M.W., Finkelstein, J.Z., Mould, S., Oscier, D., Cross, N.C. & Grand, F.H. (2008) The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre-mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1. Genes Chromosomes Cancer, 47, 379385.
  • Mustjoki, S., Hernesniemi, S., Rauhala, A., Kahkonen, M., Almqvist, A., Lundan, T. & Porkka, K. (2009) A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34). Haematologica, 94, 14691471.
  • Pui, C.H., Robison, L.L. & Look, A.T. (2008) Acute lymphoblastic leukaemia. Lancet, 371, 10301043.
  • Shtivelman, E., Lifshitz, B., Gale, R.P. & Canaani, E. (1985) Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature, 315, 550554.